ClinicalTrials.gg
Active, not recruitingNCT05897424ELEVAATE OLEUpdated Apr 13, 2026

Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema

A Phase 2 interventional study of SAR447537 in Alpha 1-Antitrypsin Deficiency and Emphysema, sponsored by Sanofi. Active, not recruiting at 40 sites in 9 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
185
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 81 studies in alpha 1-Antitrypsin Deficiency with a site in United States — 17 open to participants now, 22 under way, 5 of them phase 3. alpha 1-Antitrypsin Deficiency · United States.

Planned enrollment
5th of 55
185 · median 30
Started
2024
with 4 others
Phase 2
20 of 81
none open now
Primary completion
2028-06
later than 8 of 20 live
Registered
69th of 81
by date

Among the 81 studies in alpha 1-Antitrypsin Deficiency with a site in United States, this one is the 5th largest by planned enrollment of the 55 interventional ones that give a count, is one of 5 that started in 2024, is one of 20 in phase 2, reaches primary completion later than 8 of the 20 other live ones, and was the 69th registered.

alpha 1-Antitrypsin Deficiency

142 studies on the registry are indexed under alpha 1-Antitrypsin Deficiency; 32 are open to participants now.

Browse alpha 1-Antitrypsin Deficiency studies →

Open to participants now

17 of the 81 studies in alpha 1-Antitrypsin Deficiency with a site in United States are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 24 alpha 1-Antitrypsin Deficiency studies recruiting now, 11 (46%) set no upper age limit and 10 (42%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in alpha 1-Antitrypsin Deficiency with a site in United States, or all of them as a file.
02

Study summary

Phase 2 open label extension study to evaluate SAR447537 (INBRX-101) in adults with AATD emphysema

Read the detailed description

This is a Phase 2, Single Arm, Open Label Extension Study, Evaluating the Long-Term Safety and Clinical Efficacy of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency (AATD) Emphysema.

03

Conditions studied

  • Alpha 1-Antitrypsin Deficiency
  • Emphysema

Keywords

  • AATD
  • Alpha 1-Antitrypsin Deficiency
  • Emphysema
  • INBRX-101
  • AAT
  • SAR447537
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or females 18-80 years of age, inclusive, at the time of screening
  2. Diagnosis of AATD
  3. Evidence of emphysema secondary to AATD
  4. of ≥ 30% predicted at screening and post-bronchodilator FEV1/FVC\<0.7
  5. Current non-smoking status

Exclusion criteria

Exclusion Criteria:

For newly identified participants

  1. Receipt of A1PI augmentation therapy within 5 weeks prior to the first dose of study drug
  2. Known or suspected allergy to components of SAR447537, A1PI or human IgG
  3. Uncontrolled diabetes mellitus despite adequate antidiabetic pharmacologic treatment with a screening value ≥9%
  4. Received IV immunoglobulins, monoclonal antibodies and/or other biologic therapies within 30 days
  5. On waiting list for lung or liver transplant
  6. Acute respiratory tract infection or exacerbation within 4 weeks prior to or during screening
  7. Evidence of decompensated cirrhosis
  8. Active cancers or has a history of within 5 years prior to screening
  9. History of unstable cor pulmonale

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
185 participants (estimated)

Study arms

  • Experimental
    SAR447537 (INBRX-101)

    A1PI, Recombinant, Bivalent Fc Fusion Protein, in a solution for intravenous injection

    Drug: SAR447537

Interventions

  • DrugSAR447537

    A1PI, Recombinant, Bivalent Fc Fusion Protein

06

What researchers measure

Primary outcomes

  1. Long-term safety and tolerability

    Incidence of all treatment emergent adverse events (TEAEs), TEAEs ≥ Grade 3, serious adverse events (SAEs), TEAEs leading to discontinuation from SAR447537, and adverse events of special interest (AESIs) (including infusion-related reactions).

    Time frame: 3 years

Secondary outcomes

  1. Change in lung density by quantitative computerized tomography (CT)

    Assess the annual rate of change in lung density assessed by serial quantitative CT (15th percentile point, PD15) at total lung capacity (TLC), centrally read, from baseline to end of treatment (EoT).

    Time frame: 3 years

  2. Trough SAR447537 concentration changes

    Change in SAR447537 concentration levels from baseline to end of treatment

    Time frame: 3 years

  3. Trough serum functional AAT (fAAT) concentration changes

    Change in fAAT concentration levels from baseline to end of treatment

    Time frame: 3 years

  4. Covariate Analysis: Biometric Values: Weight

    Assessment of the impact of participant's weight \[in kg\] on the pharmacokinetic profile of SAR447537

    Time frame: 3 years

  5. Covariate Analysis: Biometric Values: Height

    Assessment of the impact of participant's height \[in cm\] on the pharmacokinetic profile of SAR447537

    Time frame: 3 years

  6. Covariate Analysis: Biometric Values: Age

    Assessment of the impact of participant's age \[in years\] on the pharmacokinetic profile of SAR447537

    Time frame: 3 years

  7. Covariate Analysis: Biometric Values: Sex

    Assessment of the impact of participant's sex \[male or female\] on the pharmacokinetic profile of SAR447537

    Time frame: 3 years

  8. Anti-drug antibodies

    Frequency of anti-drug antibodies (ADA) against SAR447537 as well as neutralizing ADA (NAb) against SAR447537

    Time frame: 3 years

07

Study locations

40 sites
  • UAB Lung Health Center- Site Number : 105
    Birmingham, Alabama 35205-2610, United States
  • St Joseph's Hospital and Medical Center- Site Number : 126
    Phoenix, Arizona 85013-4220, United States
  • David Geffen School of Medicine at UCLA- Site Number : 124
    Los Angeles, California 90095-3075, United States
  • University of California Davis Medical Center- Site Number : 110
    Sacramento, California 95817-2201, United States
  • National Jewish Medical and Research Center- Site Number : 123
    Denver, Colorado 80206-2761, United States
  • Nuvance Health Medical Practices, Pulmonary & Sleep Specialists- Site Number : 119
    Danbury, Connecticut 06810-5038, United States
  • University of Florida - Gainesville - 1600 SW Archer Rd- Site Number : 101
    Gainesville, Florida 32610-3003, United States
  • Indiana University- Site Number : 127
    Indianapolis, Indiana 46202-5128, United States
  • Brigham and Women's Hospital -75 Francis Street- Site Number : 131
    Boston, Massachusetts 02115-6105, United States
  • University of Minnesota-420 Delaware Str SE- Site Number : 125
    Minneapolis, Minnesota 55455-0341, United States
  • Hannibal Regional Healthcare System-HRMG-Hannibal- Site Number : 111
    Hannibal, Missouri 63401-6890, United States
  • Columbia University Irving Medical Center- Site Number : 104
    New York, New York 10032-3729, United States
  • Oregon Health and Science University- Site Number : 117
    Portland, Oregon 97239-3011, United States
  • Penn State Health Milton S. Hershey Medical Center- Site Number : 122
    Hershey, Pennsylvania 17033-2360, United States
  • Temple University Hospital - 3401 N Broad St- Site Number : 130
    Philadelphia, Pennsylvania 19140-5103, United States
  • Velocity Clinical Research - Spartanburg - PPDS- Site Number : 120
    Spartanburg, South Carolina 29303-4225, United States
  • Houston Methodist Hospital- Site Number : 113
    Houston, Texas 77030-2703, United States
  • University of Utah Health Care- Site Number : 106
    Salt Lake City, Utah 84132-0001, United States
  • Investigational Site Number : 202
    Chermside, Queensland 4032, Australia
  • Investigational Site Number : 204
    South Brisbane, Queensland 4101, Australia
  • Investigational Site Number : 201
    North Adelaide, South Australia 5000, Australia
  • Investigational Site Number : 207
    Box Hill, Victoria 3128, Australia
  • Investigational Site Number : 203
    Fitzroy, Victoria 3065, Australia
  • Investigational Site Number : 205
    Frankston, Victoria 3199, Australia
  • Investigational Site Number : 701
    Hellerup, 2900, Denmark
  • Investigational Site Number : 702
    Vejle, 7100, Denmark
  • Investigational Site Number : 501
    Dublin, Dublin D09 XR63, Ireland
  • Investigational Site Number : 403
    Auckland, 1051, New Zealand
  • Investigational Site Number : 404
    Wellington, 6021, New Zealand
  • Investigational Site Number : 801
    Warsaw, Masovian Voivodeship 01-138, Poland
  • Investigational Site Number : 802
    Krakow, 30-688, Poland
  • Investigational Site Number : 901
    Santander, Cantabria 39008, Spain
  • Investigational Site Number : 902
    Madrid, 28040, Spain
  • Investigational Site Number : 903
    Santiago de Compostela, 15706, Spain
  • Investigational Site Number : 601
    Gothenburg, 413 46, Sweden
  • Investigational Site Number : 308
    Dundee, Angus DD1 9SY, United Kingdom
  • Investigational Site Number : 306
    Wythenshawe, Cheshire M23 9QZ, United Kingdom
  • Investigational Site Number : 307
    Exeter, Devon EX2 5DW, United Kingdom
  • Investigational Site Number : 304
    Southampton, Hampshire SO16 6YD, United Kingdom
  • Investigational Site Number : 309
    Coventry, CV2 2DX, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2024 (actual). Primary completion is estimated for Jun 2028, 48 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2023
First posted
Jun 9, 2023
StartActual
Jun 20, 2024
Primary completionEst.
Jun 30, 2028
CompletionEst.
Sep 30, 2028
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05897424
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Jun 9, 2023
Start date
Jun 20, 2024
Primary completion
Jun 30, 2028 (estimated)
Completion
Sep 30, 2028 (estimated)
Last update
Apr 13, 2026

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion